CLPT ClearPoint Neuro Inc
Price (delayed)
$13.09
Market cap
$361.71M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.7
Enterprise value
$345.17M
ClearPoint Neuro's mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of
Highlights
CLPT's debt has shrunk by 74% YoY and by 3.4% QoQ
The gross profit has grown by 40% YoY and by 4.1% from the previous quarter
ClearPoint Neuro's EPS has increased by 22% YoY but it has decreased by 2.9% from the previous quarter
The equity has grown by 20% YoY but it has contracted by 12% from the previous quarter
The quick ratio has contracted by 32% YoY and by 29% from the previous quarter
Key stats
What are the main financial stats of CLPT
Market
Valuations
Earnings
Shares outstanding
27.63M
Market cap
$361.71M
Enterprise value
$345.17M
Price to earnings (P/E)
N/A
Price to book (P/B)
14.22
Price to sales (P/S)
11.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11
Revenue
$31.39M
Gross profit
$19.12M
Operating income
-$19.75M
Net income
-$18.91M
EBIT
-$18.91M
EBITDA
-$17.01M
Free cash flow
-$9.23M
Per share
Balance sheet
Liquidity
EPS
-$0.7
EPS diluted
-$0.7
Free cash flow per share
-$0.34
Book value per share
$0.92
Revenue per share
$1.16
TBVPS
$1.43
Total assets
$39.19M
Total liabilities
$13.8M
Debt
$3.57M
Equity
$25.39M
Working capital
$23.01M
Debt to equity
0.14
Current ratio
3.22
Quick ratio
2.4
Net debt/EBITDA
0.97
Margins
Efficiency
Dividend
EBITDA margin
-54.2%
Gross margin
60.9%
Net margin
-60.3%
Operating margin
-62.9%
Return on assets
-40.8%
Return on equity
-62.5%
Return on invested capital
-131.8%
Return on capital employed
-65.6%
Return on sales
-60.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLPT stock price
How has the ClearPoint Neuro stock price performed over time
Intraday
0%
1 week
5.06%
1 month
-9.85%
1 year
102.95%
YTD
-14.89%
QTD
10.09%
Financial performance
How have ClearPoint Neuro's revenue and profit performed over time
Revenue
$31.39M
Gross profit
$19.12M
Operating income
-$19.75M
Net income
-$18.91M
Gross margin
60.9%
Net margin
-60.3%
The gross profit has grown by 40% YoY and by 4.1% from the previous quarter
CLPT's net margin is up by 35% YoY
ClearPoint Neuro's operating margin has increased by 33% YoY
ClearPoint Neuro's revenue has increased by 31% YoY and by 3.2% from the previous quarter
Growth
What is ClearPoint Neuro's growth rate over time
Valuation
What is ClearPoint Neuro stock price valuation
P/E
N/A
P/B
14.22
P/S
11.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11
ClearPoint Neuro's EPS has increased by 22% YoY but it has decreased by 2.9% from the previous quarter
The P/B is 68% below the 5-year quarterly average of 44.8 but 53% above the last 4 quarters average of 9.3
The equity has grown by 20% YoY but it has contracted by 12% from the previous quarter
ClearPoint Neuro's revenue has increased by 31% YoY and by 3.2% from the previous quarter
The price to sales (P/S) is 28% higher than the last 4 quarters average of 8.8 but 13% lower than the 5-year quarterly average of 13.0
Efficiency
How efficient is ClearPoint Neuro business performance
ClearPoint Neuro's return on invested capital has shrunk by 67% YoY and by 28% QoQ
ClearPoint Neuro's ROS has increased by 35% YoY
The return on equity has grown by 26% year-on-year
CLPT's ROA is up by 15% YoY but it is down by 6% from the previous quarter
Dividends
What is CLPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLPT.
Financial health
How did ClearPoint Neuro financials performed over time
The company's total assets is 184% higher than its total liabilities
ClearPoint Neuro's total liabilities has decreased by 36% YoY but it has increased by 23% from the previous quarter
The current ratio has contracted by 34% YoY and by 29% from the previous quarter
CLPT's debt is 86% lower than its equity
The debt to equity has dropped by 79% year-on-year but it has increased by 8% since the previous quarter
CLPT's debt has shrunk by 74% YoY and by 3.4% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.